1 active not recruiting, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow DLBCL, Diffused Large B Cell Lymphoma: new trials by email Literature Review of DLBCL, Diffused Large B Cell Lymphoma trials Research Report on DLBCL, Diffused Large B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma NIR178, PDR001 - NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 315 | 2017-08-28 | 2024-10-09 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Head and Neck Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Spinocerebellar Degenerations (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Adenocarcinoma (1) · Brain Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Cerebellar Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1)
spartalizumab (1)
Novartis Pharmaceuticals (1) · Poseida Therapeutics, Inc. (1)
United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Singapore (1) · Spain (1) · Switzerland (1) · Taiwan (1)
2017 (1)